Individualization of antiretroviral therapy - Pharmacogenomic aspect.
| dc.contributor.author | Dalal, Bhavik | |
| dc.contributor.author | Shankarkumar, Aruna | |
| dc.contributor.author | Ghosh, K | |
| dc.date.accessioned | 2016-08-03T09:55:10Z | |
| dc.date.available | 2016-08-03T09:55:10Z | |
| dc.date.issued | 2015-12 | |
| dc.description.abstract | Combination therapy with three drug regimens for human immunodeficiency virus (HIV) infection significantly suppresses the viral replication. However, this therapeutic impact is restricted by adverse drug events and response in terms of short and long term efficacy. There are multiple factors involved in different responses to antiretrovirals (ARVs) such as age, body weight, disease status, diet and heredity. Pharmacogenomics deals with individual genetic make-up and its role in drug efficacy and toxicity. In depth genetic research has provided evidence to predict the risk of developing certain toxicities for which personalized screening and surveillance protocols may be developed to prevent side effects. Here we describe the use of pharmacogenomics for optimal use of HAART (highly active antiretroviral therapy). | en_US |
| dc.identifier.citation | Dalal Bhavik, Shankarkumar Aruna, Ghosh K. Individualization of antiretroviral therapy - Pharmacogenomic aspect. Indian Journal of Medical Research. 2015 Dec; 142(6): 663-674. | en_US |
| dc.identifier.uri | https://imsear.searo.who.int/handle/123456789/176366 | |
| dc.language.iso | en | en_US |
| dc.source.uri | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4774063/ | en_US |
| dc.subject | HAART | en_US |
| dc.subject | HIV | en_US |
| dc.subject | NNRTI | en_US |
| dc.subject | NRTI | en_US |
| dc.subject | personalized medicine | en_US |
| dc.subject | pharmacogenomics | en_US |
| dc.title | Individualization of antiretroviral therapy - Pharmacogenomic aspect. | en_US |
| dc.type | Article | en_US |